Bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC), is the most common malignant tumor of the urinary system. Although platinum-based chemotherapy has shown significant clinical efficacy as a first-line treatment, its therapeutic effect is still limited for patients with lymphovascular invasion (LVI). The formation of LVI is closely related to platelets, which not only hinder drug delivery but also protect tumor cells from chemotherapy-induced cell death and immune attack.
On August 13, 2024, Nano Letters reported that researchers achieved targeted inhibition of LVI formation and significantly improved the chemotherapy efficacy of bladder cancer by designing CREKA peptide-modified mesoporous silica nanoparticles (CREKA@LPT-MSNC) as a nanodrug.
This nanodrug has a core-shell structure, where talaporfin (talaporfin sodium) is preferentially loaded into the CREKA-modified lipid vesicle shell, and platinum is embedded in the mesoporous silica nanoparticle core. The experimental results show that CREKA@LPT-MSNC nanoparticles not only prolonged blood circulation but also had excellent tumor-targeting ability, which helped improve drug concentration at the tumor site and reduce side effects of anti-platelet therapy. In vivo anti-tumor effect showed that CREKA@LPT-MSNC effectively inhibited LVI formation, increased tumor vessel permeability, improved the exposure of tumor cells to platinum, and ultimately improved the therapeutic effect of platinum.
In addition to the excellent properties of the CREKA-modified mesoporous silica nanoparticles, the design strategies of this nanodrug are also worth exploring. The use of nucleation-induced assembly (NIA) effectively controlled the size and morphology of the mesoporous silica nanoparticles, which was crucial for tailoring their performance. The use of lipid vesicles as a drug carrier not only improved the stability and bioavailability of the nanodrug but also enhanced the tumor-targeting ability and LVI inhibition.
In conclusion, the CREKA-modified mesoporous silica nanoparticles as a nanodrug have unique advantages in inhibiting LVI formation and improving the chemotherapy efficacy of bladder cancer. This nanodrug can not only provide a new strategy for bladder cancer treatment but also have broad application prospects in other cancer types.
From Article:Targeted Inhibition of Lymphovascular Invasion Formation with CREKA Peptide-Modified Silicasomes to Boost Chemotherapy in Bladder Cancer
SAT NANO is a best supplier of mesoporous silicon dioxide nanoparticle in China, we can supply 60-80nm, 100-150nm particle size, if you have any enquiry, please feel free to contact us at sales03@satnano.com
